SCHEMBL3668049

SCHEMBL3668049

CC(C)Oc1cc(Nc2nc(N)cc([C@H](C)c3ccc(F)cn3)c2[N+](=O)[O-])n[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 13/20 0.40
JAK3 P52333 11/20 0.40
NTRK1 P04629 8/20 0.38
CDK2 P24941 3/20 0.37
LCK P06239 2/20 0.37
RET P07949 2/20 0.37
FLT3 P36888 2/20 0.37
MUSK O15146 1/20 0.37
FGFR3 P22607 1/20 0.37
CCNE1 P24864 1/20 0.37
PTK2B Q14289 1/20 0.37
AURKA O14965 3/20 0.37
NTRK3 Q16288 2/20 0.37
NTRK2 Q16620 2/20 0.37
AURKB Q96GD4 2/20 0.37
IGF1R P08069 2/20 0.37
FYN P06241 1/20 0.37
FGFR1 P11362 1/20 0.37
FLT1 P17948 1/20 0.37
LTK P29376 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3667655 0.91 JAK2 (0.37) JAK2JAK3NTRK1CDK2LCK
SCHEMBL3665548 0.89 JAK2 (0.39) JAK2JAK3NTRK1CDK2RET
SCHEMBL3774509 0.88 JAK2 (0.52) JAK2JAK3NTRK1CDK2LCK
SCHEMBL3769207 0.87 JAK2 (0.39) JAK2JAK3NTRK1CDK2LCK
SCHEMBL588501 0.82 JAK2 (0.44) JAK2JAK3NTRK1CDK2LCK
SCHEMBL588809 0.82 JAK2 (0.44) JAK2JAK3NTRK1CDK2LCK
Phosphoric Acid SCHEMBL589436 0.79 JAK2 (0.41) JAK2JAK3NTRK1CDK2LCK
SCHEMBL3780040 0.78 JAK2 (0.38) JAK2JAK3NTRK1CDK2RET
SCHEMBL588800 0.77 JAK2 (0.43) JAK2JAK3NTRK1CDK2LCK
SCHEMBL3732740 0.76 MGMT (0.38) JAK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150011545-A1 Chemical Compounds - 759 ASTRAZENECA AB (SE) 2015-01-08 US disclosed
US-20140155394-A1 Chemical Compounds - 759 ASTRAZENECA AB (SE) 2014-06-05 US disclosed
US-8486966-B2 9-(pyrazol-3-yl)-9H-purine-2-amine and 3-(pyrazol-3-yl) -3H-imidazo[4,5-B] pyridin-5-amine derivatives and their use for the treatment of cancer ASTRAZENECA AB (SE) 2013-07-16 US disclosed
US-20100324040-A1 9-(PYRAZOL-3-YL)-9H-PURINE-2-AMINE AND 3-(PYRAZOL-3-YL) -3H-IMIDAZO[4,5-B] PYRIDIN-5- AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER ASTRAZENECA AB 2010-12-23 US disclosed
EP-2152705-A1 9- (PYRAZOL- 3 -YL) - 9H- PURINE-2 -AMINE AND 3- (PYRAZ0L-3-YL) -3H-IMIDAZ0 [4, 5-B]PYRIDIN-5-AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER AstraZeneca AB (SE) 2010-02-17 EP disclosed
WO-2008135785-A1 9- (PYRAZOL- 3 -YL) - 9H- PURINE-2 -AMINE AND 3- (PYRAZ0L-3-YL) -3H-IMIDAZ0 [4, 5-B] PYRIDIN-5-AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150011545-A1 Chemical Compounds - 759 MCL1, BCL9, BCL9L JAK2 15/4885JAK3 363/4885NTRK1 4667/4885
US-20140155394-A1 Chemical Compounds - 759 MCL1, BCL9, BCL9L JAK2 15/4885JAK3 363/4885NTRK1 4667/4885
US-20100324040-A1 9-(PYRAZOL-3-YL)-9H-PURINE-2-AMINE AND 3-(PYRAZOL-3-YL) -3H-IMIDAZO[4,5-B] PYRIDIN-5- AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER THPO, MPL, MCL1 JAK2 81/4885JAK3 170/4885NTRK1 4038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.